The total return over the past 12 months is -25.49% vs. +16.94% for the S&P 500. So far it's up -46.11% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (25.49%) | (21.15%) | (24.15%) | (6.47%) | N/A | N/A |
| Total Return CAGR | (25.49%) | (21.15%) | (24.15%) | (6.47%) | N/A | N/A |
| Revenue CAGR | +12.00% | +21.62% | +1.59% | +35.53% | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
REGENXBIO Inc. (RGNX)
| Year | Start price | End price | RGNX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $14.40 | $7.76 | (46.11%) | +14.51% | (60.62%) |
| 2025 | $7.73 | $14.40 | +86.29% | +17.72% | +68.57% |
| 2024 | $17.95 | $7.73 | (56.94%) | +24.89% | (81.83%) |
| 2023 | $22.68 | $17.95 | (20.86%) | +26.19% | (47.05%) |
| 2022 | $32.70 | $22.68 | (30.64%) | (18.17%) | (12.47%) |
| 2021 | $45.36 | $32.70 | (27.91%) | +28.74% | (56.65%) |
| 2020 | $40.97 | $45.36 | +10.72% | +18.37% | (7.65%) |
| 2019 | $41.95 | $40.97 | (2.34%) | +31.22% | (33.56%) |
| 2018 | $33.25 | $41.95 | +26.17% | (4.56%) | +30.73% |
| 2017 | $18.55 | $33.25 | +79.25% | +21.70% | +57.55% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
